CORPORATE GOVERNANCE REPORT

STOCK CODE	**:**	0075
COMPANY NAME	**:**	LYC HEALTHCARE BERHAD
FINANCIAL YEAR	**:**	March 31, 2026

OUTLINE:

SECTION A – DISCLOSURE ON MALAYSIAN CODE ON CORPORATE GOVERNANCE
Disclosures in this section are pursuant to Paragraph 15.25 of Bursa Malaysia Listing Requirements.

SECTION B – DISCLOSURES ON CORPORATE GOVERNANCE PRACTICES PERSUANT CORPORATE GOVERNANCE GUIDELINES ISSUED BY BANK NEGARA MALAYSIA
Disclosures in this section are pursuant to Appendix 4 (Corporate Governance Disclosures) of the Corporate Governance Guidelines issued by Bank Negara Malaysia. This section is only applicable for financial institutions or any other institutions that are listed on the Exchange that are required to comply with the above Guidelines.

SECTION A – DISCLOSURE ON MALAYSIAN CODE ON CORPORATE GOVERNANCE
Disclosures in this section are pursuant to Paragraph 15.25 of Bursa Malaysia Listing Requirements.

Intended Outcome
Every company is headed by a board, which assumes responsibility for the company's leadership and is collectively responsible for meeting the objectives and goals of the company.

Practice 1.1
The board should set the company's strategic aims, ensure that the necessary resources are in place for the company to meet its objectives and review management performance. The board should set the company's values and standards, and ensure that its obligations to its shareholders and other stakeholders are understood and met.

Application	:	Applied
Explanation on application of the practice	:	The Board is responsible for the leadership, oversight, control, development and long-term success of the LYC Healthcare Berhad (**"LYC" or the "Company"**) and its subsidiaries (collectively referred to as the **"Group"**). It is also responsible to set the strategic directions and oversee the overall corporate strategies, key policies, management and financial matters of the Company. Besides, the Board is responsible for instilling the appropriate culture, values and behaviour throughout the Group. The roles and responsibilities of the Board and matters reserved for the Board are clearly defined in the Board Charter which can be found at the Company's website at www.lychealth.com. While the Board preserves full responsibility for monitoring the Company at all time, in discharging its responsibilities, the Board has established the Nomination Committee, Remuneration Committee and Audit Committee to perform certain of its functions and to provide it with recommendations and advices. The Board Committees' roles and responsibilities in discharging its functions are set out in the Terms of Reference of each Committees. The Board is also responsible in monitoring the effectiveness of the risk management and internal control systems to enable the potential risk to be appropriately assessed and managed. The Board sets the Company's values and standards and believes that effective corporate governance is based on honesty, integrity and transparency. The Board also values dialogue with stakeholders and appreciates the keen interest of shareholders on LYC's performance. In this regard, the Board ensures timely and relevant information about the Company is disseminated to stakeholders.
Explanation for departure	:	

<table>
<tr><td></td><td colspan="2"></td></tr>
<tr><td colspan="3">Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.</td></tr>
<tr><td>Measure :</td><td colspan="2"></td></tr>
<tr><td>Timeframe :</td><td></td><td></td></tr>
</table>

Intended Outcome
Every company is headed by a board, which assumes responsibility for the company's leadership and is collectively responsible for meeting the objectives and goals of the company.

Practice 1.2
A Chairman of the board who is responsible for instilling good corporate governance practices, leadership and effectiveness of the board is appointed.

<table>
<tr><td>Application</td><td>:</td><td colspan="2">Applied</td></tr>
<tr><td>Explanation on application of the practice</td><td>:</td><td colspan="2">The Chairman, Dato' Seri Abdul Azim bin Mohd Zabidi is responsible for instilling leadership, effectiveness, conduct and governance practice of the Company and his role and responsibilities have been set in the Board Charter of the Company.

At the Board meetings of the Company, the Chairman provides his objective views and regularly seeks the opinions of the Board members on matters being discussed during meetings and ensures that the decisions made are a representation of the Board as a whole.

The role and responsibilities of the Chairman are encapsulated in the Board Charter which is available on the Company's website at www.lychealth.com.</td></tr>
<tr><td rowspan="2">Explanation for departure</td><td rowspan="2">:</td><td colspan="2"></td></tr>
<tr><td colspan="2"></td></tr>
<tr><td colspan="4">Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.</td></tr>
<tr><td>Measure</td><td>:</td><td colspan="2"></td></tr>
<tr><td>Timeframe</td><td>:</td><td></td><td></td></tr>
</table>

Intended Outcome
Every company is headed by a board, which assumes responsibility for the company's leadership and is collectively responsible for meeting the objectives and goals of the company.

Practice 1.3
The positions of Chairman and CEO are held by different individuals.

<table>
<tr><td>Application</td><td>:</td><td colspan="2">Applied</td></tr>
<tr><td>Explanation on application of the practice</td><td>:</td><td colspan="2">The position of the Chairman and Managing Director of the Company are held by two separate individual to engender accountability and facilitate clear division of responsibilities to ensure that there is a balance of power and authority in the Company. The Chairman is Dato' Seri Abdul Azim bin Mohd Zabidi whilst the Managing Director is Mr. Sui Diong Hoe. The Board also has delegated the Management of the Group to the Managing Director, assisted by the Management team.

The respective roles and responsibilities of the Chairman and the Managing Director are clearly articulated in the Board Charter of the Company.

The segregation of roles facilitates a healthy open exchange of views between the Board and Management in their deliberation of business, strategic aims and key activities of the Company.</td></tr>
<tr><td rowspan="2">Explanation for departure</td><td rowspan="2">:</td><td colspan="2"></td></tr>
<tr><td colspan="2"></td></tr>
<tr><td colspan="4">Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.</td></tr>
<tr><td>Measure</td><td>:</td><td colspan="2"></td></tr>
<tr><td>Timeframe</td><td>:</td><td></td><td></td></tr>
</table>

Intended Outcome
Every company is headed by a board, which assumes responsibility for the company's leadership and is collectively responsible for meeting the objectives and goals of the company.

Practice 1.4
The Chairman of the board should not be a member of the Audit Committee, Nomination Committee or Remuneration Committee

<table>
<tr><td colspan="4">Note: If the board Chairman is not a member of any of these specified committees, but the board allows the Chairman to participate in any or all of these committees' meetings, by way of invitation, then the status of this practice should be a 'Departure'.</td></tr>
<tr><td>Application</td><td>:</td><td colspan="2">Applied</td></tr>
<tr><td>Explanation on application of the practice</td><td>:</td><td colspan="2">The Chairman of the Board, Dato' Seri Abdul Azim bin Mohd Zabidi, who is an Independent Non-Executive Director is not a member of Audit and Risk Management Committee, Nomination Committee and Remuneration Committee.

The Board Committees' Terms of Reference and selection criteria were stipulate clearly that the Board Chairman shall not be appointed as a member of any Board Committees.</td></tr>
<tr><td rowspan="2">Explanation for departure</td><td rowspan="2">:</td><td colspan="2"></td></tr>
<tr><td colspan="2"></td></tr>
<tr><td colspan="4">Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.</td></tr>
<tr><td>Measure</td><td>:</td><td colspan="2"></td></tr>
<tr><td>Timeframe</td><td>:</td><td></td><td></td></tr>
</table>

Intended Outcome
Every company is headed by a board, which assumes responsibility for the company's leadership and is collectively responsible for meeting the objectives and goals of the company.

Practice 1.5
The board is supported by a suitably qualified and competent Company Secretary to provide sound governance advice, ensure adherence to rules and procedures, and advocate adoption of corporate governance best practices.

Application	:	Applied	
Explanation on application of the practice	:	The Board is supported by two (2) qualified Chartered Secretaries who are members of The Malaysian Institute of Chartered Secretaries and Administrators (MAICSA). The Directors have unrestricted access to the advice and services of the Company Secretaries to enable them to discharge their duties effectively. The Board is regularly updated and advised by the Company Secretaries who are professionally qualified, experienced and knowledgeable on new or revised regulatory requirements as well as corporate governance best practice. In this respect, the Company Secretaries play an advisory role to the Board, particularly with regard to the Company's Constitution, Board policies and procedures, and its compliance with regulatory requirements, and advocate adoption of corporate governance best practices. The Company Secretaries constantly keep themselves abreast of changes in the realm of corporate governance through continuous professional development. During the financial year under review, they attended pertinent internal and external trainings on changes in regulatory requirements and corporate governance.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome

Every company is headed by a board, which assumes responsibility for the company's leadership and is collectively responsible for meeting the objectives and goals of the company.

Practice 1.6
Directors receive meeting materials, which are complete and accurate within a reasonable period prior to the meeting. Upon conclusion of the meeting, the minutes are circulated in a timely manner.

Application	:	Applied	
Explanation on application of the practice	:	All Directors are furnished with the agenda of meetings together with due notice, Board or Board Committees papers and reports at least five (5) business days prior to the Board and Board Committees meetings to allow the Board to have sufficient time to go through the meeting materials in order to have a conducive and meaningful discussion in the meeting. Exceptions may be made for certain ad-hoc or urgent instances where Directors unanimously consent to a shorter notice period and elapsed timeframe for the provision of agenda papers. The Board or Board Committees papers are prepared by the Management to provide accurate and quality information, which includes but not limited to updates on financial, operational and legal related matters that enable informed decision making to be performed smoothly at the meeting. All pertinent issues deliberated and concluded at the Board meeting are duly recorded by the Company Secretaries in the minutes of meetings. The minutes of meetings of Board and Board committees are circulated to all Directors.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
There is demarcation of responsibilities between the board, board committees and management.

There is clarity in the authority of the board, its committees and individual directors.

Practice 2.1
The board has a board charter which is periodically reviewed and published on the company's website. The board charter clearly identifies–
- the respective roles and responsibilities of the board, board committees, individual directors and management; and
- issues and decisions reserved for the board.

<table>
<tr><td>Application</td><td>:</td><td colspan="2">Applied</td></tr>
<tr><td>Explanation on application of the practice</td><td>:</td><td colspan="2">The Board Charter has been incorporated into the Group's governance system, which clearly sets out the roles, functions, composition and operation of the Board, having regard to the principles of good corporate governance and requirements of ACE Market Listing Requirements of Bursa Malaysia Securities Berhad.

There is a formal schedule of matters reserved for the Board's consideration and decision which is set out in the Board Charter.

A copy of the Board Charter and Terms of Reference of the Audit and Risk Management Committee, Remuneration Committee and Nomination Committee are available in the Company's website at www.lychealth.com.</td></tr>
<tr><td rowspan="2">Explanation for departure</td><td rowspan="2">:</td><td colspan="2"></td></tr>
<tr><td colspan="2"></td></tr>
<tr><td colspan="4">Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.</td></tr>
<tr><td>Measure</td><td>:</td><td colspan="2"></td></tr>
<tr><td>Timeframe</td><td>:</td><td></td><td></td></tr>
</table>

Intended Outcome
The board is committed to promoting good business conduct and maintaining a healthy corporate culture that engenders integrity, transparency and fairness.

The board, management, employees and other stakeholders are clear on what is considered acceptable behaviour and practice in the company.

Practice 3.1
The board establishes a Code of Conduct and Ethics for the company, and together with management implements its policies and procedures, which include managing conflicts of interest, preventing the abuse of power, corruption, insider trading and money laundering.

The Code of Conduct and Ethics is published on the company's website.

Application	:	Applied	
Explanation on application of the practice	:	The Company has established a Code of Conduct and Ethics to promote a corporate culture which engenders ethical conduct that permeates throughout the Group based on the principles in relation to sincerity, integrity, responsibility and corporate social responsibility. The Code of Conduct and Ethics covers the following overarching areas:- • Equal treatment of all employees; • Ensure a safe and secure working environment; • Environmental protection; • Avoidance of accepting gifts and business courtesies; • Maintain, complete and accurate business records; • Ensure high integrity and professionalism; • Ensure protection of confidential information; • Compliance with laws including abuse of power, corruption, insider trading and money laundering; • Corporate Governance; and • Conflict of interest. A copy of the Code of Conduct and Ethics is available in the Company's website at www.lychealth.com.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
The board is committed to promoting good business conduct and maintaining a healthy corporate culture that engenders integrity, transparency and fairness.

The board, management, employees and other stakeholders are clear on what is considered acceptable behaviour and practice in the company.

Practice 3.2
The board establishes, reviews and together with management implements policies and procedures on whistleblowing.

Application	:	Applied	
Explanation on application of the practice	:	The Group has a whistleblowing policy setting out procedures to provide all employees of the Group and other interested parties an avenue where genuine concerns related to possible improprieties in matters of financial reporting, compliance and other malpractices can be objectively investigated and addressed. The details on the policy and procedures can be found on the Company's website at www.lychealth.com.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
The company addresses sustainability risks and opportunities in an integrated and strategic manner to support its long-term strategy and success.

Practice 4.1
The board together with management takes responsibility for the governance of sustainability in the company including setting the company's sustainability strategies, priorities and targets.

The board takes into account sustainability considerations when exercising its duties including among others the development and implementation of company strategies, business plans, major plans of action and risk management.

Strategic management of material sustainability matters should be driven by senior management.

Application	:	Applied	
Explanation on application of the practice	:	The Board together with the Management takes responsibility for the governance of sustainability of the Company, including setting the Company's sustainability strategies, priorities and targets. Performance against these targets are communicated to the Company's internal and external stakeholders. In line with the recommendation of the MCCG, the Board takes into consideration the Company's performance in managing material sustainability risks and opportunities when determining the appropriate level of remuneration for the Directors and Senior Management.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
The company addresses sustainability risks and opportunities in an integrated and strategic manner to support its long-term strategy and success.

Practice 4.2
The board ensures that the company's sustainability strategies, priorities and targets as well as performance against these targets are communicated to its internal and external stakeholders.

Application	:	Applied	
Explanation on application of the practice	:	The Company's stakeholders as well as the environment is crucial to sustaining the Group's long-term performance. The Board factors in these sustainability considerations and ensures that the Company's strategies, priorities and targets are communicated to internal and external stakeholders. As such the Company incorporates Economic, Environment and Social ("**EES**") risks and opportunities into the business decisions given their heightened materiality in decision making considerations of stakeholders. The Company's Sustainability Statement can be found on the Annual Report 2026.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
The company addresses sustainability risks and opportunities in an integrated and strategic manner to support its long-term strategy and success.

Practice 4.3
The board takes appropriate action to ensure they stay abreast with and understand the sustainability issues relevant to the company and its business, including climate-related risks and opportunities.

Application :	Applied	
Explanation on application of the practice :	The Board is updated by the Management on sustainability issues relevant to the Company. The sustainability efforts undertaken by the Company, are determined based on Environmental, Social, and Governance ("**ESG**"). The Board had been constantly keeping abreast by attending suitable training programmes which are relevant to the Company and its business so as to equip itself with and to enhance its environment, social and governance competency.	
Explanation for departure :		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure :		
Timeframe :		

Intended Outcome
The company addresses sustainability risks and opportunities in an integrated and strategic manner to support its long-term strategy and success.

Practice 4.4
Performance evaluations of the board and senior management include a review of the performance of the board and senior management in addressing the company's material sustainability risks and opportunities.

Application :	Applied	
Explanation on application of the practice :	The performance evaluation form for the Board incorporates elements of ESG and undertook an evaluation of the performance of the Board and Senior Management in addressing the Company's material sustainability risks and opportunities.	
Explanation for departure :		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure :		
Timeframe :		

Intended Outcome
The company addresses sustainability risks and opportunities in an integrated and strategic manner to support its long-term strategy and success.

Practice 4.5- Step Up
The board identifies a designated person within management, to provide dedicated focus to manage sustainability strategically, including the integration of sustainability considerations in the operations of the company.

Note: The explanation on adoption of this practice should include a brief description of the responsibilities of the designated person and actions or measures undertaken pursuant to the role in the financial year.		
Application	:	Not Adopted
Explanation on adoption of the practice	:	

Intended Outcome
Board decisions are made objectively in the best interests of the company taking into account diverse perspectives and insights.

Practice 5.1
The Nomination Committee should ensure that the composition of the board is refreshed periodically. The tenure of each director should be reviewed by the Nomination Committee and annual re-election of a director should be contingent on satisfactory evaluation of the director's performance and contribution to the board.

Application :	Applied	
Explanation on application of the practice :	The Nomination Committee ("**NC**") reviews the composition, tenure, skills and experience matrix of the Board annually. The NC assessed the performance of the Directors standing for re-election at the Company's 22nd Annual General Meeting via the annual evaluation of the Board. Amongst others, the Board evaluation assessed the Directors' competencies, commitment, contribution, performance, independence, and their ability to act in the best interest of the Company as a whole.	
Explanation for departure :		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure :		
Timeframe :		

Intended Outcome
Board decisions are made objectively in the best interests of the company taking into account diverse perspectives and insights.

Practice 5.2
At least half of the board comprises independent directors. For Large Companies, the board comprises a majority independent directors.

Application	:	Applied	
Explanation on application of the practice	:	As of 31 March 2026, the Board comprises majority Independent Directors. It has five (5) Directors, comprising the Chairman (Independent Non-Executive Director), three (3) Independent Non-Executive Directors and one (1) Executive Director. The Board's composition complies with the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad which requires a minimum of two (2) Directors or 1/3 of the Board, whichever is higher to be Independent Directors. The presence of majority Independent Directors allow Board's deliberations and decisions to be made objectively in the best interest of the Company. The current size and composition of the Board is within a range which is appropriate. The Board also believes that the current size of the Board is sufficient to enable its Committees to be structured properly to operate and being dynamic and responsive to the needs of the Group. The spread of age, gender and background of the Directors that the Board as a whole has the appropriate blend of skills, knowledge and experience, from a wide range of industries and backgrounds, necessary to lead the Group.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
Board decisions are made objectively in the best interests of the company taking into account diverse perspectives and insights.

Practice 5.3
The tenure of an independent director does not exceed a cumulative term limit of nine years. Upon completion of the nine years, an independent director may continue to serve on the board as a non-independent director.

If the board intends to retain an independent director beyond nine years, it should provide justification and seek annual shareholders' approval through a two-tier voting process.

Application	:	Applied	
Explanation on application of the practice	:	In accordance to the Company's Board Charter, the maximum tenure of an independent non-executive Director shall not exceed the cumulative term of nine years from the date of first appointment as Director or upon the expiry of the on-going term of appointment as Director whichever is the later. The Board is mindful of the recommendation of the Code that the tenure of an Independent Director should not exceed a cumulative term of nine (9) years. Any extension beyond nine years will require the Board's justification and shareholder approval unless the said Director is redesignated as a non-independent non-executive Director. In the event the Board continues to retain the Independent Director after the nine (9) years, an annual shareholders' approval would be sought through a two-tier voting process in order to retain the said Director as an Independent Director.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
Board decisions are made objectively in the best interests of the company taking into account diverse perspectives and insights.

Practice 5.4 - Step Up
The board has a policy which limits the tenure of its independent directors to nine years without further extension.

Note: To qualify for adoption of this Step Up practice, a listed issuer must have a formal policy which limits the tenure of an independent director to nine years without further extension i.e. shareholders' approval to retain the director as an independent director beyond nine years.		
Application	:	Not Adopted
Explanation on adoption of the practice	:	

Intended Outcome
Board decisions are made objectively in the best interests of the company taking into account diverse perspectives and insights.

Practice 5.5
Appointment of board and senior management are based on objective criteria, merit and with due regard for diversity in skills, experience, age, cultural background and gender.

Directors appointed should be able to devote the required time to serve the board effectively. The board should consider the existing board positions held by a director, including on boards of non-listed companies. Any appointment that may cast doubt on the integrity and governance of the company should be avoided.

<table>
<tr><td>Application :</td><td colspan="2">Applied</td></tr>
<tr><td>Explanation on application of the practice :</td><td colspan="2">The Company is committed in ensuring that the Board and Senior Management are sufficiently diverse and appropriately balanced.

This is further supported by the annual assessment carried out by the Nomination Committee ("NC"). The NC concluded that the skills, experience, age and gender of the Board satisfy the requirements of the skills matrix and that the Chairman of the Board possesses the leadership to safeguard the stakeholders' interest and ensure the development of the Company.</td></tr>
<tr><td>Explanation for departure :</td><td colspan="2"></td></tr>
<tr><td></td><td colspan="2"></td></tr>
<tr><td colspan="3">Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.</td></tr>
<tr><td>Measure :</td><td colspan="2"></td></tr>
<tr><td>Timeframe :</td><td></td><td></td></tr>
</table>

Intended Outcome
Board decisions are made objectively in the best interests of the company taking into account diverse perspectives and insights.

Practice 5.6
In identifying candidates for appointment of directors, the board does not solely rely on recommendations from existing board members, management or major shareholders. The board utilises independent sources to identify suitably qualified candidates.

If the selection of candidates was based on recommendations made by existing directors, management or major shareholders, the Nominating Committee should explain why these source(s) suffice and other sources were not used.

Application	:	Applied
Explanation on application of the practice	:	In view of the need to ensure proper processes are in place to manage composition and also succession issues at board level, an appropriate process for the selection, nomination and appointment of suitable candidates to the Board has been put in place. The Board authorises the Nomination Committee ("**NC**") the option of using external independent sources, if required, in the recruitment of candidates for directorship above and beyond referrals from shareholders, Directors and Senior Management. The NC is also entrusted with the responsibility of screening and conducting an initial selection by assessing and considering the capabilities, commitment and qualities of candidates to be appointed as Board Members. Prior to the submission of its recommendations to the Board on the selection and appointment of a Director, , the NC will take into account of the Board Skills Matrix, Board Diversity Policy, Fit & Proper Policy, competencies, experiences, integrity, and also considered, inter-alia, the current directorships of companies held by the candidates and any potential conflict of interest/risk. Aside from that, the NC also will undertake additional verifications prior to the appointments, which includes background checks on the individual's character and bankruptcy search to qualify as Directors. Potential candidates who are identified to be appointed as an Independent Non-Executive Director ("**INED**") are required to declare/confirm that he/she meets the criteria of an Independent Director in accordance with the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad prior recommending to the Board for its approval on his/her proposed appointment as an INEDs. Besides, the potential candidates for appointment as member of the Board of LYC shall also require to complete the fit and proper declaration as per the Fit & Proper Policy of the Company.

Explanation for departure :		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure :		
Timeframe :		

Intended Outcome
Board decisions are made objectively in the best interests of the company taking into account diverse perspectives and insights.

Practice 5.7
The board should ensure shareholders have the information they require to make an informed decision on the appointment and reappointment of a director. This includes details of any interest, position or relationship that might influence, or reasonably be perceived to influence, in a material respect their capacity to bring an independent judgement to bear on issues before the board and to act in the best interests of the listed company as a whole. The board should also provide a statement as to whether it supports the appointment or reappointment of the candidate and the reasons why.

Application	:	Applied	
Explanation on application of the practice	:	Shareholders are kept informed on the Board's decisions in respect of the appointment of Directors via announcements to Bursa Securities and updates on the Company's website. The profiles of Directors that are published in the Annual Report include their age, gender, date of appointment and last re-election, directorships in other companies, working experience and any conflict of interest with the Company, if any. The performance of each Director subject for re-election had been assessed through the annual Board Evaluation. The areas of assessment of such Directors include their personal/professional profile, attendance record, training activities, character and attitude, governance, and independence. The Board had endorsed the NRC's assessment that it is satisfied with the performance and effectiveness of those Directors who are to be standing for re-election.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
Board decisions are made objectively in the best interests of the company taking into account diverse perspectives and insights.

Practice 5.8
The Nominating Committee is chaired by an Independent Director or the Senior Independent Director.

Application	:	Applied
Explanation on application of the practice	:	The NC is chaired by Mr. Mohd Khasan Bin Ahmad, an Independent Non-Executive Director of the Company. Profile of Mr. Mohd Khasan bin Ahmad can be found on the Annual Report 2026.
Explanation for departure	:	
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure	:	
Timeframe		

Intended Outcome
Board decisions are made objectively in the best interests of the company taking into account diverse perspectives and insights.

Practice 5.9
The board comprises at least 30% women directors.

Application	:	Departure	
Explanation on application of the practice	:	Please provide an explanation on how the practice is being applied.	
Explanation for departure	:	As of 31 March 2026, the Board comprises five (5) members, one (1) of whom is woman Director. The current Board composition complies with the ACE Market Listing Requirements, and the Board is of the view that the current diversity of the Board is sufficient to execute its duties and responsibilities, as explained in Practice 5.5 above.	
		The Board, through its Nomination Committee ("**NC**"), will continue to take steps to ensure that suitable women candidates are sought and considered as part of the recruitment exercise. This will be done over time, taking into consideration the present size of the Board, the merit and suitability of women candidates and the evolving challenges to the Company from time to time. The critical attributes of a suitable Board candidate include skills, knowledge, expertise and experience, professionalism, character, competence, commitment (including time commitment) and integrity that the candidate shall bring to the Board.	
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
Board decisions are made objectively in the best interests of the company taking into account diverse perspectives and insights.

Practice 5.10
The board discloses in its annual report the company's policy on gender diversity for the board and senior management.

Application :	Applied	
Explanation on application of the practice :	The Company's Policy on Gender Diversity is incorporated in the Board Diversity Policy that sets out the Board's approach to diversity. Selection of Board candidates are based on a range of diverse perspectives, including but not limited to professional experiences, business experiences, skills, knowledge, gender, ethnicity and educational background. The ultimate decision will be based on merit and contribution that the selected candidates will bring to the Board. Selection of Senior Management is based on objective criteria, merit and with due regard for diversity in skills, experience, age, cultural background and gender.	
Explanation for departure :		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure :		
Timeframe :		

Intended Outcome
Stakeholders are able to form an opinion on the overall effectiveness of the board and individual directors.

Practice 6.1
The board should undertake a formal and objective annual evaluation to determine the effectiveness of the board, its committees and each individual director. The board should disclose how the assessment was carried out its outcome, actions taken and how it has or will influence board composition.

For Large Companies, the board engages an independent expert at least every three years, to facilitate objective and candid board evaluation.

<table>
<tr><td colspan="2">Note: For a Large Company to qualify for adoption of this practice, it must undertake annual board evaluation and engage an independent expert at least every three years to facilitate the evaluation.</td></tr>
<tr><td>Application :</td><td>Applied</td></tr>
<tr><td>Explanation on application of the practice :</td><td>During the year, the Board has conducted an internally facilitated Board assessment via the Nomination Committee (“NC”). The assessment took into account the contribution and performance of the Directors in relation to their competencies, time commitment, and experience in meeting the needs of the Company.

The assessment and comments by Directors are summarised and discussed at the NC meeting and reported at the Board Meeting by the Chairman of NC. All assessments and evaluations carried out by the NC in the discharge of its functions are properly documented.

Based on the recent assessment, the Board was comfortable with the outcome and that the skills and experience of the current Directors satisfy the requirements of the skills matrix. The Chairman of the Board also possesses the leadership to safeguard the stakeholders’ interest and ensure the Group’s profitable performance. The Directors, Board Committees and key officers had also discharged their responsibilities in a commendable manner and contributed to the overall effectiveness of the Board and Company.

The Board engages the Company Secretaries who are from an independent external secretarial firm to facilitate the Board evaluation via evaluation forms and informal discussion with the NC.</td></tr>
<tr><td rowspan="2">Explanation for departure :</td><td></td></tr>
<tr><td></td></tr>
</table>

<table>
<tr><td colspan="3">Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.</td></tr>
<tr><td>Measure :</td><td colspan="2"></td></tr>
<tr><td>Timeframe :</td><td></td><td></td></tr>
</table>

Intended Outcome

The level and composition of remuneration of directors and senior management take into account the company's desire to attract and retain the right talent in the board and senior management to drive the company's long-term objectives.

Remuneration policies and decisions are made through a transparent and independent process.

Practice 7.1

The board has remuneration policies and procedures to determine the remuneration of directors and senior management, which takes into account the demands, complexities and performance of the company as well as skills and experience required. The remuneration policies and practices should appropriately reflect the different roles and responsibilities of non-executive directors, executive directors and senior management. The policies and procedures are periodically reviewed and made available on the company's website.

Application	:	Applied	
Explanation on application of the practice	:	The Company has adopted a Remuneration Policy for the Group's Directors and Senior Management with the main objective to provide fair and competitive remuneration to its Board and Senior Management in order for the Company to attract and retain Directors and Senior Management of calibre to run the Group successfully. A copy of the Remuneration Policy is available in the Company's website at www.lychealth.com.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
The level and composition of remuneration of directors and senior management take into account the company's desire to attract and retain the right talent in the board and senior management to drive the company's long-term objectives.

Remuneration policies and decisions are made through a transparent and independent process.

Practice 7.2
The board has a Remuneration Committee to implement its policies and procedures on remuneration including reviewing and recommending matters relating to the remuneration of board and senior management.

The Committee has written Terms of Reference which deals with its authority and duties and these Terms are disclosed on the company's website.

Application	:	Applied	
Explanation on application of the practice	:	The Remuneration Committee has been established to review and recommend the remuneration of the Executive Director and Senior Management of the Company for the Board's approval pursuant to the Terms of Reference of Remuneration Committee. The Directors' fees and benefits payable to Directors have also been reviewed and recommended by the Remuneration Committee to the Board to seek shareholders' approval at the Company's forthcoming Annual General Meeting pursuant to the Constitution of the Company. No Director is involved in deciding his own remuneration. A copy of the Terms of Reference of the Remuneration Committee is available in the Company's website at www.lychealth.com.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
Stakeholders are able to assess whether the remuneration of directors and senior management is commensurate with their individual performance, taking into consideration the company's performance.

Practice 8.1
There is detailed disclosure on named basis for the remuneration of individual directors. The remuneration breakdown of individual directors includes fees, salary, bonus, benefits in-kind and other emoluments.

Application :	Applied
Explanation on application of the practice :	In line with best corporate governance practice, the details of the Company's Directors' remuneration are made transparent and accessible to shareholders and stakeholders. The detailed disclosure of the remuneration breakdown of Individual Directors of the Company received from the Company and the Group during the financial year ended 31 March 2026 is set out in the table below.

No	Name	Directorate	Company (RM'000)							Group (RM'000)						
			Fee	Allowance	Salary	Bonus	Benefits-in-kind	Other emoluments	Total	Fee	Allowance	Salary	Bonus	Benefits-in-kind	Other emoluments	Total
1	Sui Diong Hoe	Executive Director	72	-	924	-	-	123	1,119	72	-	924	-	-	123	1,119
2	Dato' Seri Abdul Azim bin Mohd Zabidi	Independent Director	108	9	-	-	-	-	117	108	9	-	-	-	-	117
3	Mohd Khasan bin Ahmad	Independent Director	72	19	-	-	-	-	91	72	19	-	-	-	-	91
4	Dato' Muraly Daran A/L Narayana Meno	Independent Director	24	10	-	-	-	-	34	24	10	-	-	-	-	34
5	Poh Zuan Yin	Independent Director	42	13	-	-	-	-	55	42	13	-	-	-	-	55
6	Kong Sin Seng	Independent Director	72	14	-	-	-	-	76	72	14	-	-	-	-	76
7	Zalina binti Jaflus	Independent Director	36	4	-	-	-	-	40	36	4	-	-	-	-	40

Intended Outcome
Stakeholders are able to assess whether the remuneration of directors and senior management is commensurate with their individual performance, taking into consideration the company's performance.

Practice 8.2
The board discloses on a named basis the top five senior management's remuneration component including salary, bonus, benefits in-kind and other emoluments in bands of RM50,000.

Application	:	Departure	
Explanation on application of the practice	:		
Explanation for departure	:	Recognising the confidential and commercially sensitive nature of remuneration matters and prioritising the stability and continuity of business operations with a competent and experienced management team, the Board opined that there is no necessity for the Group to disclose the top five senior management's remuneration on a named basis. While acknowledging the importance of transparency in disclosing senior management remuneration, the Board is cautious of potential negative impacts on its business interests. Given the highly competitive human resource environment in which the Group operates, this will facilitate opportunities for competitors to pinch the Group's senior management. Consequently, disclosing specific remuneration details may lead to recruitment and talent retention challenges in the future.	
		Notwithstanding the above, the Board is of the view that the disclosure of the top five senior management's remuneration on a named basis will not be in the best interest of the Company and will adopt the disclosure of top five senior management's aggregated remuneration on an unnamed basis in the bands of RM100,000 in the Annual Report.	
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

No	Name	Position	Company (RM'000)					
			Salary	Allowance	Bonus	Benefits	Other emoluments	Total
1	Input info here	Input info here	Choose an item.	Choose an item.	Choose an item.	Choose an item.	Choose an item.	Choose an item.
2	Input info here	Input info here	Choose an item.	Choose an item.	Choose an item.	Choose an item.	Choose an item.	Choose an item.
3	Input info here	Input info here	Choose an item.	Choose an item.	Choose an item.	Choose an item.	Choose an item.	Choose an item.
4	Input info here	Input info here	Choose an item.	Choose an item.	Choose an item.	Choose an item.	Choose an item.	Choose an item.
5	Input info here	Input info here	Choose an item.	Choose an item.	Choose an item.	Choose an item.	Choose an item.	Choose an item.

Intended Outcome
Stakeholders are able to assess whether the remuneration of directors and senior management is commensurate with their individual performance, taking into consideration the company's performance.

Practice 8.3 - Step Up
Companies are encouraged to fully disclose the detailed remuneration of each member of senior management on a named basis.

Application	:	Not Adopted
Explanation on adoption of the practice	:	

No	Name	Position	Company ('000)					
			Salary	Allowance	Bonus	Benefits	Other emoluments	Total
1	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here
2	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here
3	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here
4	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here
5	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here	Input info here

Intended Outcome
There is an effective and independent Audit Committee.

The board is able to objectively review the Audit Committee's findings and recommendations. The company's financial statement is a reliable source of information.

Practice 9.1
The Chairman of the Audit Committee is not the Chairman of the board.

Application :	Applied	
Explanation on application of the practice :	The Chairman of the Board is Dato' Seri Abdul Azim bin Mohd Zabidi whilst the Chairman of Audit and Risk Management Committee ("**ARMC**") is Mr. Kong Sin Seng, an Independent Non-Executive Director ("**INED**"). As of 31 March 2026, the ARMC comprises three (3) members, which are all Independent Non-Executive Directors. With the position of Board Chairman and ARMC Chairman held by different individuals, the Board is able to objectively review the ARMC's findings and recommendations. The composition of the ARMC, including its roles and responsibilities, number of meetings and attendance of ARMC and summary of activities during the financial year under review are set out under the ARMC Report of the Annual Report 2026.	
Explanation for departure :		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure :		
Timeframe :		

Intended Outcome
There is an effective and independent Audit Committee.

The board is able to objectively review the Audit Committee's findings and recommendations. The company's financial statement is a reliable source of information.

Practice 9.2
The Audit Committee has a policy that requires a former partner of the external audit firm of the listed company to observe a cooling-off period of at least three years before being appointed as a member of the Audit Committee.

Application	:	Applied	
Explanation on application of the practice	:	The Audit and Risk Management Committee ("**ARMC**") has included in its Terms of Reference that a former partner of the external audit firm of the Company is required to observe a cooling-off period of at least three (3) years before being appointed as a member of the ARMC. A copy of the Terms of Reference of the ARMC is available on the Company's website at www.lychealth.com.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
There is an effective and independent Audit Committee.

The board is able to objectively review the Audit Committee's findings and recommendations. The company's financial statement is a reliable source of information.

Practice 9.3
The Audit Committee has policies and procedures to assess the suitability, objectivity and independence of the external auditor to safeguard the quality and reliability of audited financial statements.

Application	:	Applied
Explanation on application of the practice	:	The Terms of Reference of Audit and Risk Management Committee ("**ARMC**") and External Auditors Assessment Policy have been established to enable the ARMC to carry out its duties and provide the guideline to the ARMC to assess the suitability, objectivity, independence and performance of the appointed external auditors. This includes reviewing the audit plan, scope and nature of audit, discussing the contracts the Company enters into with the external auditor for the provision of non-audit services, reviewing the external auditor's evaluation of the system of internal controls and obtaining written assurance from the external auditor confirming its independence and ethical responsibilities throughout the conduct of audit engagement. In discharging the duty, the ARMC carry out annual assessment on the performance of the External Auditors on the following areas: - (a) Service quality; (b) Sufficiency of resources; (c) Communication with the Management; (d) Independence, Objectivity and Professionalism; (e) Ability to meet deadlines in providing services and responding to issues in a timely manner as contemplated in the external audit plan; (f) The nature of the non-audit fees provided and fees paid for such services related to the audit fee; and (g) Whether there are safeguards in place to ensure there is no threat to the objectivity and independence of the audit arising from the provision of non-audit services or tenure of the external auditors. In the financial year under review, the ARMC met with the External Auditors without the presence of the Executive Director and Management to discuss any issues arising from the audit exercise or any significant matters. The external auditors declare their independence through their audit engagement in accordance with all relevant professional and regulatory requirements to the ARMC on an annual basis.

<table>
<tr><td rowspan="2">Explanation for departure</td><td rowspan="2">:</td><td colspan="2"></td></tr>
<tr><td colspan="2"></td></tr>
<tr><td colspan="4">Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.</td></tr>
<tr><td>Measure</td><td>:</td><td colspan="2"></td></tr>
<tr><td>Timeframe</td><td>:</td><td></td><td></td></tr>
</table>

Intended Outcome
There is an effective and independent Audit Committee.

The board is able to objectively review the Audit Committee's findings and recommendations. The company's financial statement is a reliable source of information.

Practice 9.4 - Step Up
The Audit Committee should comprise solely of Independent Directors.

Application	:	Adopted
Explanation on adoption of the practice	:	As of 31 March 2026, the Audit and Risk Management Committee comprise solely of Independent Non-Executive Directors.

Intended Outcome
There is an effective and independent Audit Committee.

The board is able to objectively review the Audit Committee's findings and recommendations. The company's financial statement is a reliable source of information.

Practice 9.5
Collectively, the Audit Committee should possess a wide range of necessary skills to discharge its duties. All members should be financially literate, competent and are able to understand matters under the purview of the Audit Committee including the financial reporting process.

All members of the Audit Committee should undertake continuous professional development to keep themselves abreast of relevant developments in accounting and auditing standards, practices and rules.

Application	:	Applied	
Explanation on application of the practice	:	All members of the Audit and Risk Management Committee ("**ARMC**") possess a considerable understanding of financial reporting and auditing processes. They also have the necessary accounting, financial, banking, commercial and capital markets skills required to meet their responsibilities and provide an effective level of challenge to Management. All ARMC members received ongoing training and development as detailed in the Directors' Training section of the Corporate Governance Statement of the Annual Report 2026. An annual assessment on the performance of the ARMC during the term of office was undertaken by the Nomination Committee ("**NC**") for the financial year 2026 and the NC was satisfied with its performance.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
Companies make informed decisions about the level of risk they want to take and implement necessary controls to pursue their objectives.

The board is provided with reasonable assurance that adverse impact arising from a foreseeable future event or situation on the company's objectives is mitigated and managed.

Practice 10.1
The board should establish an effective risk management and internal control framework.

Application	:	Applied	
Explanation on application of the practice	:	The Group has adopted a Risk Management and Internal Control framework to continuously identify, evaluate, monitor and to manage significant tasks that materially affect the corporate objectives of the Group. The Audit and Risk Management Committee is entrusted to discharge the duties and responsibilities of reviewing the effectiveness of the Group's system of internal control.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
Companies make informed decisions about the level of risk they want to take and implement necessary controls to pursue their objectives.

The board is provided with reasonable assurance that adverse impact arising from a foreseeable future event or situation on the company's objectives is mitigated and managed.

Practice 10.2
The board should disclose the features of its risk management and internal control framework, and the adequacy and effectiveness of this framework.

<table>
<tr><td>Application :</td><td colspan="2">Applied</td></tr>
<tr><td>Explanation on application of the practice :</td><td colspan="2">The Board is aware of its responsibilities over the Group's internal control and risk management. Hence, the Board has established a framework to formulate and review risk management policies and risk strategies. The Enterprise Risk Management framework has been adopted by the Group in order to achieve such objective.

Features of the risk management framework and internal control processes are disclosed in the Statement of Risk Management and Internal Control of the Annual Report 2026.</td></tr>
<tr><td rowspan="2">Explanation for departure :</td><td colspan="2"></td></tr>
<tr><td colspan="2"></td></tr>
<tr><td colspan="3">Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.</td></tr>
<tr><td>Measure :</td><td colspan="2"></td></tr>
<tr><td>Timeframe :</td><td></td><td></td></tr>
</table>

Intended Outcome
Companies make informed decisions about the level of risk they want to take and implement necessary controls to pursue their objectives.

The board is provided with reasonable assurance that adverse impact arising from a foreseeable future event or situation on the company's objectives is mitigated and managed.

Practice 10.3 - Step Up
The board establishes a Risk Management Committee, which comprises a majority of independent directors, to oversee the company's risk management framework and policies.

Application	:	Adopted
Explanation on adoption of the practice	:	The members of ARMC comprised wholly of Independent Non-Executive Directors.

Intended Outcome
Companies have an effective governance, risk management and internal control framework and stakeholders are able to assess the effectiveness of such a framework.

Practice 11.1
The Audit Committee should ensure that the internal audit function is effective and able to function independently.

<table>
<tr><td>Application</td><td>:</td><td colspan="2">Applied</td></tr>
<tr><td>Explanation on application of the practice</td><td>:</td><td colspan="2">The Audit and Risk Management Committee ("ARMC") of the Company is responsible for monitoring and reviewing the effectiveness of the Group's Internal Audit function. The Internal Audit function is independent and is led by the Internal Auditor, outsourced to GovernanceAdvisory.com Sdn. Bhd., a professional services provider, who has a direct reporting line to the ARMC.

The Internal Auditor has access to all relevant records, personnel and properties within the Group to carry out its duties. The Internal Auditor is independently reviewing the risk identification procedures and control processes implemented by the Management, conducts audit that encompass review of critical areas being identified, and reports to AC on quarterly basis as well as its findings, management's responses and recommendations.

During the financial year 31 March 2026, the ARMC had private session with the Internal Auditors for discussion on audit related matters and activities without the presence of Management.</td></tr>
<tr><td rowspan="2">Explanation for departure</td><td rowspan="2">:</td><td colspan="2"></td></tr>
<tr><td colspan="2"></td></tr>
<tr><td colspan="4">Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.</td></tr>
<tr><td>Measure</td><td>:</td><td colspan="2"></td></tr>
<tr><td>Timeframe</td><td>:</td><td></td><td></td></tr>
</table>

Intended Outcome
Companies have an effective governance, risk management and internal control framework and stakeholders are able to assess the effectiveness of such a framework.

Practice 11.2
The board should disclose–
- whether internal audit personnel are free from any relationships or conflicts of interest, which could impair their objectivity and independence;
- the number of resources in the internal audit department;
- name and qualification of the person responsible for internal audit; and
- whether the internal audit function is carried out in accordance with a recognised framework.

Application	:	Applied
Explanation on application of the practice	:	The Company's internal audit function is independent from the Company's business operations and activities and the Internal Auditor is report directly to The Audit and Risk Management Committee ("**ARMC**") This reporting relationship supports internal audit independence and objectivity, which assures adequate consideration of audit recommendations and planned corrective actions. The relationship also gives the Internal Audit staff the authority needed for full, free and unrestricted access to any or all operations, records, property and personnel within the Group. The internal audit function of the Group has been outsourced to GovernanceAdvisory.com Sdn. Bhd., a professional services provider. The professional service provider is headed by Mr. Jason Tee who reports to the ARMC. He is a member of the Malaysian Institute of Accountants ("**MIA**") and Certified Practising Accountant ("**CPA**") Australia. He is supported by a team of qualified and experienced internal audit professionals. GovernanceAdvisory.com Sdn. Bhd. has assigned three (3) staffs to provide internal audit services to the group during the financial year. The internal audit personnel assigned by the Outsource Internal Auditors are free from any relationships or conflicts of interest that could impair their independence and objectivity for those internal audit assignments performed during the financial year. The Internal Auditors performed their work by referring to a recognized framework, such as the International Professional Practices Framework ("**IPPF**") issued by the Institute of Internal Auditors.
Explanation for departure	:	
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		

Measure :		
Timeframe :		

Intended Outcome
There is continuous communication between the company and stakeholders to facilitate mutual understanding of each other's objectives and expectations.

Stakeholders are able to make informed decisions with respect to the business of the company, its policies on governance, the environment and social responsibility.

Practice 12.1
The board ensures there is effective, transparent and regular communication with its stakeholders.

Application	:	Applied	
Explanation on application of the practice	:	The Board is aware of the importance of an effective communication with the stakeholders of the Group and has formalised a corporate disclosure policies and procedures. The corporate disclosures policies and procedures through the organization's functions enable comprehensive, accurate and timely information relating to the Company to be disclosed to the shareholders and other stakeholders. The Group's financial performance, major corporate developments and other relevant information are promptly disseminated to shareholders and investors via announcements of its quarterly results, annual report, corporate announcements to Bursa Securities and press conferences. It is the Group's practice that any material information for public announcement, including annual report, quarterly financial statements, press releases, and presentation to investors, analyst and media are factual and reviewed internally before issuance to ensure accuracy and is expressed in a clear and objective manner. A copy of the corporate disclosure policies and procedures are available on Company's website at www.lychealth.com.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
There is continuous communication between the company and stakeholders to facilitate mutual understanding of each other's objectives and expectations.

Stakeholders are able to make informed decisions with respect to the business of the company, its policies on governance, the environment and social responsibility.

Practice 12.2
Large companies are encouraged to adopt integrated reporting based on a globally recognised framework.

Application :	Not applicable – Not a Large Company	
Explanation on application of the practice :		
Explanation for departure :		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure :		
Timeframe :		

Intended Outcome
Shareholders are able to participate, engage the board and senior management effectively and make informed voting decisions at General Meetings.

Practice 13.1
Notice for an Annual General Meeting should be given to the shareholders at least 28 days prior to the meeting.

Application	:	Applied	
Explanation on application of the practice	:	The Notice of the 21st Annual General Meeting ("**AGM**") was circulated at least twenty-eight (28) days before the date of the meeting to provide shareholders sufficient notice and time to consider the resolutions that will be discussed and decided at the AGM. The Notice of forthcoming AGM will continue to be given at least twenty-eight (28) days prior to the meeting.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
Shareholders are able to participate, engage the board and senior management effectively and make informed voting decisions at General Meetings.

Practice 13.2
All directors attend General Meetings. The Chair of the Audit, Nominating, Risk Management and other committees provide meaningful response to questions addressed to them.

Application	:	Applied	
Explanation on application of the practice	:	During the AGM of the Company in year 2026, all Directors had attended the AGM to address any questions from the shareholders directly. The AGM is the principal forum for dialogue with shareholders. Shareholders are provided with an opportunity to participate in the question and answer session in which shareholders may raise questions pertaining to the business activities of the Company and resolutions tabled at the meeting.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

Intended Outcome
Shareholders are able to participate, engage the board and senior management effectively and make informed voting decisions at General Meetings.

Practice 13.3
Listed companies should leverage technology to facilitate–
- voting including voting in absentia; and
- remote shareholders' participation at general meetings.

Listed companies should also take the necessary steps to ensure good cyber hygiene practices are in place including data privacy and security to prevent cyber threats.

Application	:	Departure
Explanation on application of the practice	:	
Explanation for departure	:	The Board will consider where possible the convenience of shareholders in selecting a suitable and appropriate location to hold its Annual General Meeting ("**AGM**"). The last AGM was held in Dewan Berjaya, Bukit Kiara Equestrian & Country Resort, Jalan Bukit Kiara, Off Jalan Damansara, 60000 Kuala Lumpur, Malaysia.
		Shareholders who are unable to attend the AGM are advised that they can appoint proxies to attend and vote on their behalf by completing the proxy form enclosed in the Annual Report and depositing it at the Registered Office at least forty-eight (48) hours before the time for holding the meeting or any adjournment thereof. Explanation for each proposed resolution set out in the Notice of AGM will be provided during AGM to assist shareholders in making their decisions and exercising their voting rights. All resolutions set out in the Notice of AGM were put to vote by poll. The Company had appointed an independent scrutineer to validate the vote cast in the last AGM. The outcome of the AGM was then announced to Bursa Securities on the same meeting day while the summary of key matters discussed during the AGM were posted on the Company website. Nevertheless, if required by the regulatory authorities to conduct remote meetings, the Group will adopt technologies to conduct the meeting remotely.
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure	:	

Timeframe :	Others	As and when appropriate

Intended Outcome
Shareholders are able to participate, engage the board and senior management effectively and make informed voting decisions at General Meetings.

Practice 13.4
The Chairman of the board should ensure that general meetings support meaningful engagement between the board, senior management and shareholders. The engagement should be interactive and include robust discussion on among others the company's financial and non-financial performance as well as the company's long-term strategies. Shareholders should also be provided with sufficient opportunity to pose questions during the general meeting and all the questions should receive a meaningful response.

Note: The explanation of adoption of this practice should include a discussion on measures undertaken to ensure the general meeting is interactive, shareholders are provided with sufficient opportunity to pose questions and the questions are responded to.		
Application :	Applied	
Explanation on application of the practice :	The Chairman views the engagements among the Board, Senior Management and shareholders in earnest. Shareholders are eligible to pose questions including but not limited to financial and non-financial performances, and long-term strategies of the Group. The Company received questions from the shareholders/proxy holders during the 21st Annual General Meeting ("**AGM**") and the Board had provided meaningful response to every question. The questions raised by the shareholders/proxy holders and responded by the Board were minuted and the minutes of the 21st AGM is available online on the Company's website at www.lychealth.com.	
Explanation for departure :		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure :		
Timeframe :		

Intended Outcome
Shareholders are able to participate, engage the board and senior management effectively and make informed voting decisions at General Meetings.

Practice 13.5
The board must ensure that the conduct of a virtual general meeting (fully virtual or hybrid) support meaningful engagement between the board, senior management and shareholders. This includes having in place the required infrastructure and tools to support among others, a smooth broadcast of the general meeting and interactive participation by shareholders. Questions posed by shareholders should be made visible to all meeting participants during the meeting itself.

Note: The explanation of adoption of this practice should include a discussion on measures undertaken to ensure the general meeting is interactive, shareholders are provided with sufficient opportunity to pose questions and the questions are responded to. Further, a listed issuer should also provide brief reasons on the choice of the meeting platform.		
Application :	Not applicable – only physical general meetings were conducted in the financial year	
Explanation on application of the practice :		
Explanation for departure :		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.		
Measure :		
Timeframe :		

Intended Outcome
Shareholders are able to participate, engage the board and senior management effectively and make informed voting decisions at General Meetings.

Practice 13.6
Minutes of the general meeting should be circulated to shareholders no later than 30 business days after the general meeting.

Note: The publication of Key Matters Discussed is not a substitute for the circulation of minutes of general meeting.			
Application	:	Applied	
Explanation on application of the practice	:	The minutes of the Annual General Meeting ("**AGM**") was made available at the Company's website at www.lychealth.com no later than 30 business days after the completion of the 21st AGM.	
Explanation for departure	:		
Large companies are required to complete the columns below. Non-large companies are encouraged to complete the columns below.			
Measure	:		
Timeframe	:		

SECTION B – DISCLOSURES ON CORPORATE GOVERNANCE PRACTICES PERSUANT CORPORATE GOVERNANCE GUIDELINES ISSUED BY BANK NEGARA MALAYSIA

Disclosures in this section are pursuant to Appendix 4 (Corporate Governance Disclosures) of the Corporate Governance Guidelines issued by Bank Negara Malaysia. This section is only applicable for financial institutions or any other institutions that are listed on the Exchange that are required to comply with the above Guidelines.
